203 related articles for article (PubMed ID: 24091769)
1. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
[TBL] [Abstract][Full Text] [Related]
2. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.
Belmonte F; Das S; Sysa-Shah P; Sivakumaran V; Stanley B; Guo X; Paolocci N; Aon MA; Nagane M; Kuppusamy P; Steenbergen C; Gabrielson K
Am J Physiol Heart Circ Physiol; 2015 Oct; 309(8):H1271-80. PubMed ID: 26254336
[TBL] [Abstract][Full Text] [Related]
4. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
5. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
Fedele C; Riccio G; Coppola C; Barbieri A; Monti MG; Arra C; Tocchetti CG; D'Alessio G; Maurea N; De Lorenzo C
Breast Cancer Res Treat; 2012 Jun; 133(2):511-21. PubMed ID: 21947749
[TBL] [Abstract][Full Text] [Related]
6. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Xu Z; Gao Z; Fu H; Zeng Y; Jin Y; Xu B; Zhang Y; Pan Z; Chen X; Zhang X; Wang X; Yan H; Yang X; Yang B; He Q; Luo P
Cardiovasc Res; 2023 May; 119(5):1250-1264. PubMed ID: 36651911
[TBL] [Abstract][Full Text] [Related]
7. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2013 Mar; 13(1):33-47. PubMed ID: 22948710
[TBL] [Abstract][Full Text] [Related]
8. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
11. RhNRG-1β Protects the Myocardium against Irradiation-Induced Damage via the ErbB2-ERK-SIRT1 Signaling Pathway.
Gu A; Jie Y; Sun L; Zhao S; E M; You Q
PLoS One; 2015; 10(9):e0137337. PubMed ID: 26332771
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
14. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
[TBL] [Abstract][Full Text] [Related]
17. Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.
Maulik A; Davidson SM; Piotrowska I; Walker M; Yellon DM
Cardiovasc Drugs Ther; 2018 Jun; 32(3):245-253. PubMed ID: 29766336
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
Pandey S; Kuo WW; Shen CY; Yeh YL; Ho TJ; Chen RJ; Chang RL; Pai PY; Viswanadha VP; Huang CY; Huang CY
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C235-C243. PubMed ID: 31116582
[TBL] [Abstract][Full Text] [Related]
19. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.
Mukhopadhyay P; Rajesh M; Bátkai S; Kashiwaya Y; Haskó G; Liaudet L; Szabó C; Pacher P
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1466-83. PubMed ID: 19286953
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
